{"id":58987,"date":"2024-09-03T00:05:18","date_gmt":"2024-09-03T00:05:18","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/09\/03\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/"},"modified":"2024-09-03T00:05:18","modified_gmt":"2024-09-03T00:05:18","slug":"vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/","title":{"rendered":"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1\/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older"},"content":{"rendered":"<div>\n<p align=\"left\">SAN CARLOS, Calif., Sept.  02, 2024  (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the Phase 1\/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the Company\u2019s 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older.<\/p>\n<p align=\"left\">To participate in the conference call, please dial 800-225-9448 (domestic) or 203-518-9708 (international) and refer to conference ID PCVX0903. A live webcast of the conference call will also be available on the investor relations page of the\u00a0Vaxcyte corporate website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s8BNAr41HlHhvn-IcaHZQSTGffXZqpJHWR4-53nxoPrfY1672ZsUtBhZYU0l2_wptFKbylm0QlPbhEnahbxQPn78POaUhgkc3DIEoxP_UgJq2TgEV3qGYiMH2QiNepy6cBD4L6EU3zmTZIFy6MvDCRDjYJmi1V5ddl-LmMqHfnKitV9nWc4arZPVYhfXPJLnRJHnlIouJ2Mhrcs8XSIuK-XcEy0vXQoWHeU4SJG7_6o=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.vaxcyte.com\">www.vaxcyte.com<\/a>. After the live webcast, the event will remain archived on the\u00a0Vaxcyte website for 30 days.<\/p>\n<p align=\"left\"><strong>About Vaxcyte<\/strong><br \/>Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte\u2019s lead candidate, VAX-24, is a Phase 3-ready 24-valent, broad-spectrum, carrier-sparing PCV being developed for the prevention of IPD. VAX-31, the Company\u2019s next-generation 31-valent PCV, is the broadest-spectrum PCV candidate in the clinic today. Both VAX-24 and VAX-31 are designed to improve upon the standard-of-care PCVs for both children and adults by covering the serotypes that are responsible for a significant portion of IPD in circulation and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.<\/p>\n<p align=\"left\">Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF&#x2122; cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company\u2019s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte\u2019s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s8BNAr41HlHhvn-IcaHZQV-iL_ydKJNAdAIAxcp7qMRXEc9cTVqUsUr8RjQ6N3LprvhntaSXCL4LFzCCumbNr0h1vBcALi7TtHetUVC8JyRBV0mEexgIE4V8y-NZNfxQ-IvEaR8us4q9iwHde8qQUtYcixScr0uUMZ_sNGV0BWIodayfO3P0GRo_1KW4ETqhyBNRD45WzoQ6Wqnv8FXlzpIaDRTWDxVZjucUOtpgCE9WoiIs53WFkAjVMeZp8qRI3GLzc76a4eP5HFyedQOIJMA1NzWtkwAmFZeXY1gYh8faRYZ2DPpYaO3YGWZVzjfXTT7W3MInGrmBQRPaeebsPhigGvLr7z0yhbdTb-HtkEmDG2arqChGF2pBZw8pfO0_6xAg1sPoSX5JcEmB2r0JTlrNLrexaseEuGFkRaJ1wa0=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.vaxcyte.com\">www.vaxcyte.com<\/a>.<\/p>\n<p align=\"left\"><strong>Contacts:<\/strong><\/p>\n<p align=\"left\">Patrick Ryan, Executive Director, Corporate Communications<br \/>Vaxcyte, Inc.<br \/>415-606-5135<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=94TF8Z4SbvMe6scsatxrnv0FhzG_kXkviXfa0rbFZVeW_EKde_gIbM7DyhY25iCXk_tkjrGmWVkubeHRVYCuonJG181Dr8IQ_KamRExFSIIaHc-T2-ruZhhEbebLxH5CMthHP1cQlJxMXF4VaSkkiKasgsfUwmTP_CHZud3g-geLNPeJoAsBjh05D6cbHAeot_D3cLKbNCu1goEhxeRk2zxAZqXHUX8xtApS6Mq041-hkDqlSEO10XdsdG5i5QOT\" rel=\"nofollow noopener\" target=\"_blank\" title=\"media@vaxcyte.com\">media@vaxcyte.com<\/a><\/p>\n<p align=\"left\">Jennifer Zibuda, Senior Director, Investor Relations\u00a0<br \/>Vaxcyte, Inc.<br \/>860-729-8902<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fiEagIbT8wQvg0hRA4MIB7tsC94uQMxpCMWk0Nqki8pWEP-c6tvFTGlnB8aVto2_yP9dwCE_SyLbSKc0gnZF0u22Uwx8hTaqxovHSwVD6PWIDIFXFAjlLsgvDmknIYI1GlKd4DjwkxsWYHfZYQ7xU8paGtZa2997zTTjcKzDqCv4wM0OFlTZzD53NJ1RzGlH1JX7sXDT30oKK-wypZYnFiPe61435D1clhGFEI8rNp6eTGMHXML-unUs0uHSYK2-_9D9MBOJTpECA7ABQL7INQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"investors@vaxcyte.com\">investors@vaxcyte.com<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjMyZTRjYmQtOGQ0Zi00ZDA1LTg2M2UtYzQyZTBhNzJlODQ4LTEyMDczNzc=\/tiny\/Vaxcyte-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the [&#8230;]\n","protected":false},"author":1,"featured_media":58988,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-58987","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1\/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1\/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older\" \/>\n<meta property=\"og:description\" content=\"SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-03T00:05:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/09\/Vaxcyte-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1\/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older\",\"datePublished\":\"2024-09-03T00:05:18+00:00\",\"dateModified\":\"2024-09-03T00:05:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/\"},\"wordCount\":458,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/\",\"name\":\"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1\/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-09-03T00:05:18+00:00\",\"dateModified\":\"2024-09-03T00:05:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1\/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1\/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/","og_locale":"en_US","og_type":"article","og_title":"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1\/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older","og_description":"SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high","og_url":"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-09-03T00:05:18+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/09\/Vaxcyte-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1\/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older","datePublished":"2024-09-03T00:05:18+00:00","dateModified":"2024-09-03T00:05:18+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/"},"wordCount":458,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/","url":"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/","name":"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1\/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-09-03T00:05:18+00:00","dateModified":"2024-09-03T00:05:18+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/vaxcyte-to-host-webcast-and-conference-call-to-present-topline-results-from-phase-1-2-study-of-vax-31-its-31-valent-pneumococcal-conjugate-vaccine-candidate-in-adults-aged-50-and-older\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1\/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/58987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=58987"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/58987\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/58988"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=58987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=58987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=58987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}